Skip to main content
SpringerLink
Log in

Diagnosis of Colorectal Liver Metastases

  • Chapter
  • First Online:
Colorectal Cancer Liver Metastases

  • 966 Accesses

Abstract

The incidence of colorectal cancer (CRC) is high, and 50–60% of colorectal cancer patients will progress with distant metastases. The liver is the most common site for CRC and the diagnosis can be made preoperatively, during the initial presentation of the disease, intraoperatively, or during the follow-up after the treatment of the primary. This diagnosis is based in clinical, laboratory, and radiological studies. This chapter will address the different circumstances of the diagnosis and the role of each of the present diagnostic tools.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.

    Article  PubMed  Google Scholar 

  2. Cheng L, Eng C, Nieman LZ, Kapadia AS, Du XL. Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. Am J Clin Oncol. 2011;34(6):573–80.

    Article  PubMed  Google Scholar 

  3. Henley SJ, Singh SD, King J, Wilson R, O’Neil ME, Ryerson AB, et al. Invasive cancer incidence and survival–United States, 2011. MMWR Morb Mortal Wkly Rep. 2015;64(9):237–42.

    PubMed  PubMed Central  Google Scholar 

  4. INCA – Instituto Nacional de Câncer – Estimativa 2018 [Internet]. [cited 2018 Apr 23]. Available from: http://www.inca.gov.br/estimativa/2018/.

  5. Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13(10):1271–80.

    Article  PubMed  Google Scholar 

  6. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997;15(3):938–46. 6. Sheth KR, Clary BM. Management of hepatic metastases from colorrectal cancer. Clin Colon Rectal Surg. 2005;18(3):215–23.

    Article  PubMed  CAS  Google Scholar 

  7. Pozzo C, Basso M, Cassano A, Quirino M, Schinzari G, Trigila N, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorrectal cancer patients. Ann Oncol. 2004;15:933–9.

    Article  PubMed  CAS  Google Scholar 

  8. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244(2):254–9.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Welch JP, Donaldson GA. The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann Surg. 1979;189(4):496–502.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Mantke R, Schmidt U, WolffS KR, Lippert H. Incidence of synchronous liver metastases in patients with colorectal cancer in relationship to clinico-pathologic characteristics. Results of a German prospective multicenter observational study. Eur J Surg Oncol. 2012;38(3):259–65.

    Article  PubMed  CAS  Google Scholar 

  11. Lupinacci RM, Coelho FF, Perini MV, Lobo EJ, Ferreira FG, Szutan LA, et al. Current management of liver metastases from colorectal cancer: recommendations of the São Paulo Liver Club. Rev Col Bras Cir. 2013;40(3):251–60.

    Article  PubMed  Google Scholar 

  12. Ghiringhelli F, Hennequin A, Drouillard A, Lepage C, Faivre J, Bouvier AM. Epidemiology and prognosis of synchronous and metachronous colon cancer metastases: a French population-based study. Dig Liver Dis. 2014;46(9):854–8.

    Article  PubMed  Google Scholar 

  13. Pugh S, Fuller A, Rose P, Perera-Salazar R, Mellor J, George S, et al. What is the true incidence of metachronous colorectal liver metástases? Evidence from the UK FACS (follow-up after colorectal surgery) trial. Gut (Medical Abstracts). 2012;61(Suppl 2):A24.

    Google Scholar 

  14. Paschos KA, Majeed AW, Bird NC. Natural history of hepatic metastases from colorectal cancer--pathobiological pathways with clinical significance. World J Gastroenterol. 2014;20(14):3719–37.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Sugarbaker PH. Colorectal cancer: prevention and management of metastatic disease. Biomed Res Int. 2014;2014:782890.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Haddad JD, You DM. Colorectal cancer screening and race in an equal access medical system. J Community Health. 2016;41(1):78–81.

    Article  PubMed  Google Scholar 

  17. Haddad AJ, Bani Hani M, Pawlik TM, Cunningham SC. Colorectal liver metastases. Int J Surg Oncol. 2011;2011:285840.

    PubMed  PubMed Central  Google Scholar 

  18. Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27:872–7. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19124803.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Seo SI, Lim SB, Yoon YS, et al. Comparison of recurrence patterns between </=5 years and >5 years after curative operations in colorectal cancer patients. J Surg Oncol. 2013;108:9–13. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23754582.

    Article  PubMed  Google Scholar 

  20. Smith JJ, D’Angelica MI. Surgical management of hepatic metastases of colorectal cancer. Hematol Oncol Clin North Am. 2015;29(1):61–84.

    Article  PubMed  Google Scholar 

  21. Lepage C, Phelip JM, Cany L, et al. Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer: the FFCD PRODIGE 13 randomised phase III trial. Dig Liver Dis. 2015;47:529–31. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25933809.

    Article  PubMed  Google Scholar 

  22. Kahi CJ, Boland CR, Dominitz JA, et al. Colonoscopy surveillance after colorectal cancer resection: recommendations of the US Multi- Society Task Force on Colorectal Cancer. Gastroenterology. 2016;150:758–768 e711. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26892199.

    Article  PubMed  Google Scholar 

  23. Rosati G, Ambrosini G, Barni S, et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma. Ann Oncol. 2016;27:274–80. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26578734.

    Article  PubMed  CAS  Google Scholar 

  24. Rex DK, Kahi CJ, Levin B, Smith RA, Bond JH, Brooks D, Burt RW, Byers T, Fletcher RH, Hyman N, Johnson D, Kirk L, Lieberman DA, Levin TR, O’Brien MJ, Simmang C, Thorson AG, Winawer SJ. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2006;130(6):1865–71.

    Article  PubMed  Google Scholar 

  25. Pedruzzi PAG, Hoeldtke E, Tomasich FDS, Dias LAN, Kato M. Metástase hepática – Estudo de 115 casos. Rev Soc Bras Cancerol. 2003;24(4):06–12.

    Google Scholar 

  26. Slesser AA, Khan F, Chau I, Khan AZ, Mudan S, Tekkis PP, Brown G, Rao S. The effect of a primary tumour resection on the progression of synchronous colorectal liver metastases: an exploratory study. Eur J Surg Oncol [Internet]. Elsevier Ltd. 2015;41(4):484–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25638603.

    Article  CAS  Google Scholar 

  27. Bendell JC, Bekaii-Saab TS, Cohn AL, Hurwitz HI, Kozloff M, Tezcan H, et al. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist [Internet]. 2012;17(12):1486–95. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3528380&tool=pmcentrez&rendertype=abstract.

    Article  CAS  Google Scholar 

  28. Litvka A, Cercek A, Segal N, et al. False-positive elevations of carcinoembryonic antigen in patients with a history of resected colorectal cancer. J Natl Compr Canc Netw. 2014;12:907–13. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24925201.

    Article  Google Scholar 

  29. Nicholson BD, Shinkins B, Pathiraja I, et al. Blood CEA levels for detecting recurrent colorectal cancer. Cochrane Database Syst Rev. 2015:CD011134. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26661580.

  30. Nicholson BD, Shinkins B, Mant D. Blood measurement of carcinoembryonic antigen level for detecting recurrence of colorectal cancer. JAMA. 2016;316:1310–1. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27673308.

    Article  PubMed  Google Scholar 

  31. Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:3213–21.

    Article  PubMed  Google Scholar 

  32. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32:579–86.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Siravegna G, Bardelli A. Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance. Genome Biol. 2014;15:449.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Montagut C, Dalmases A, Bellosillo B, et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med. 2012;18:221–3.

    Article  PubMed  CAS  Google Scholar 

  35. Meyerhardt JA, Mangu PB, Flynn PJ, et al. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American society of clinical oncology clinical practice guideline endorsement. J Clin Oncol. 2013;31:4465–70. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24220554.

    Article  PubMed  Google Scholar 

  36. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer. Cancer Care Ontario. 2016. Available at: https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=124839. Accessed 15 Aug 2016.

  37. Steele SR, Chang GJ, Hendren S, et al. Practice guideline for the surveillance of patients after curative treatment of colon and rectal cancer. Dis Colon Rectum. 2015;58:713–25. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26163950

    Article  PubMed  Google Scholar 

  38. Floriani I, Torri V, Rulli E, et al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging. 2010;31:19–31.

    Article  PubMed  Google Scholar 

  39. Reiter MJ, Hannemann NP, Schwope RB, Lisanti CJ, Learn PA. Role of imaging for patients with colorectal hepatic metastases: what the radiologist needs to know. Abdom Imaging. 2015;40(8):3029–42.

    Article  PubMed  Google Scholar 

  40. Bartolotta TV, Taibbi A, Midiri M, et al. Characterisationof focal liverlesionsundeterminedatgrey-scale US: contrast-enhanced US versus 64-row MDCT and MRI withliver-specificcontrastagent. Radiol Med. 2010;115:714–31.

    Article  PubMed  CAS  Google Scholar 

  41. Weg N, Scheer MR, Gabor MP. Liver lesions: improved detection with dual-detector-array CT and routine 2.5 mm thin collimation. Radiology. 1998;209:417–26.

    Article  PubMed  CAS  Google Scholar 

  42. Adams RB, Aloia TA, Loyer E, et al. Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB. 2013;15:91–103.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Frankel TL, D’Angelica MI. Hepatic resection for colorectal metastases. J Surg Oncol. 2014;109:2–7.

    Article  PubMed  Google Scholar 

  44. Wiering B, Krabbe PF, Jager GJ, Oyen WJ, Ruers TJ. The impact of fluorine-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer. 2005;104:2658–70.

    Article  PubMed  Google Scholar 

  45. Zhuang H, Sinha P, Pourdehnad M, et al. The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver. Nucl Med Commun. 2000;21:793–8.

    Article  PubMed  CAS  Google Scholar 

  46. Moulton CA, Gu CS, Law CH, et al. Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial. JAMA. 2004;311:1863–9.

    Article  CAS  Google Scholar 

  47. Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology. 2010;257:674–84.

    Article  PubMed  Google Scholar 

  48. Scharitzer M, Ba-Ssalamah A, Ringl H, et al. Preoperative evaluation of colorectal liver metastases: comparison between gadoxetic acid-enhanced 3.0-T MRI and contrast-enhanced MDCT with histopathological correlation. Eur Radiol. 2013;23:2187–96.

    Article  PubMed  CAS  Google Scholar 

  49. Han K, Park SH, Kim KW, et al. Use of liver magnetic resonance imaging after standard staging abdominopelvic computed tomography to evaluate newly diagnosed colorectal cancer patients. Ann Surg. 2015;261:480–6.

    Article  PubMed  Google Scholar 

  50. Patel S, Cheek S, Osman H, Jeyarajah DH. MRI with gadoxetate disodium for colorectal liver metastasis: is it the new “imaging modality of choice”? J Gastrointest Surg. 2014;18:2130–5.

    Article  PubMed  Google Scholar 

  51. Zech CJ, Korpraphong P, Huppertz A, et al. Randomized multicentre trial of gadoxetic acid-enhanced MRI vs. Conventional MRI or CT in the staging of colorectal cancer liver metastases. Br J Surg. 2014;101:613–21.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  52. Kim HJ, Lee SS, Byun JH, et al. Incremental valueofliver MR imaging in patientswithpotentiallycurablecolorectalhepaticmetastasisdetectedat CT: a prospective comparison of diffusion weighted imaging, gadoxetic acid-enhanced MR imaging, and a combination of both MR techniques. Radiology. 2015;274:712–22.

    Article  PubMed  Google Scholar 

  53. Cho JY, Lee YJ, Han HS, et al. Role of gadoxetic acid enhanced magnetic resonance imaging in the preoperative evaluation of small hepatic lesions in patients with colorectal cancer. World J Surg. 2015;39:1161–6.

    Article  PubMed  Google Scholar 

  54. Donati OF, Fischer MA, Chuck N, et al. Accuracy and confidence of Gd-EOB-DTPA enhanced MRI and diffusion weighted imaging alone and in combination for the diagnosis of liver metastases. Eur J Radiol. 2013;82:822–8.

    Article  PubMed  Google Scholar 

  55. Lafaro KJ, Roumanis P, Demirjian A, Lall C, Imagawa DK. Gd-EOB-DTPA-enhanced MRI for detection of liver metastases from colorectal cancer: a surgeon’s perspective! Int J Hepatol. 2013;2013:572307.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Kanematsu M, Kondo H, Goshima S, et al. Imaging liver metastases: review and update. Eur J Radiol. 2006;58:217–28.

    Article  PubMed  Google Scholar 

  57. Boonsirikamchai P, Asran MA, Maru DM, et al. CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumab. Am J Roentgenol. 2011;197:W1060–6.

    Article  Google Scholar 

  58. Sica GT, Ji H, Ros PR. CT and MR imaging of hepatic metastases. Am J Roentgenol. 2000;174:691–8.

    Article  CAS  Google Scholar 

  59. Jones EC, Chezmar JL, Nelson RC, Bernardino ME. The frequency and significance of small (<15 mm) hepatic lesions detected by CT. AJR Am J Roentgenol. 1992;158:535–9.

    Article  PubMed  CAS  Google Scholar 

  60. Schwartz LH, Gandras EJ, Colangelo SM, Ercolani MC, Panicek DM. Prevalence and importance of small hepatic lesions found at CT in patients with cancer. Radiology. 1999;210:71–4.

    Article  PubMed  CAS  Google Scholar 

  61. Gore RM, Pickhardt PJ, Mortele KJ, Fishman EK, Horowitz JM, Fimmel CJ, Talamonti MS, Berland LL, Pandharipande PV. Management of incidental liver lesions on CT: a white paper of the ACR Incidental Findings Committee. J Am Coll Radiol. 2017;14(11):1429–37.

    Article  PubMed  Google Scholar 

  62. van Kessel CS, Buckens CF, van den Bosch MA, et al. Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis. Ann Surg Oncol. 2012;19:2805–13.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Kulemann V, Schima W, Tamandl D, et al. Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI? Eur J Radiol. 2011;79:e1–6.

    Article  PubMed  Google Scholar 

  64. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422.

    Article  PubMed  Google Scholar 

  65. Coimbra FJF, Ribeiro HSC, Marques MC. I Consenso brasileiro de tratamento multidisciplinar de metástase hepática colorretais. Módulo 1: Avaliação pré-tratamento. ABCD Arq Bras Cir Dig. 2015;28(4):222–30.

    Article  PubMed  Google Scholar 

  66. Benson AB 3rd, Venook AP, Al-Hawary MM, et al. NCCN guidelines insights: colon cancer, version 2.2018. J Natl Compr Canc Netw. 2018;16(4):359–69.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Brazilian Society of Surgical Oncology, Rio de Janeiro, Brazil

    Roberto Heleno Lopes, Bruno Roberto Braga Azevedo, Phillipe Abreu-Reis & Alexandre Ferreira Oliveira

  2. University Hospital of the Federal University of Juiz de Fora, Juiz de Fora, Brazil

    Roberto Heleno Lopes & Alexandre Ferreira Oliveira

  3. São Vicente Hospital, São Vicente, Brazil

    Bruno Roberto Braga Azevedo

  4. Federal University of Juiz de Fora, Juiz de Fora, Brazil

    André Noronha Arvellos & Alexandre Ferreira Oliveira

Authors
  1. Roberto Heleno Lopes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bruno Roberto Braga Azevedo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. André Noronha Arvellos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Phillipe Abreu-Reis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alexandre Ferreira Oliveira
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. National Cancer Institute, Rio de Janeiro, Brazil

    Mauro Monteiro Correia

  2. Banner MD Anderson Cancer Center, Phoenix, AZ, USA

    Michael A. Choti

  3. Virginia Mason Medical Center, Seattle, WA, USA

    Flavio G. Rocha

  4. Center for Advanced Treatment of HBP Diseases, Ageo Central General Hospital, Ageo Shi, Saitama, Japan

    Go Wakabayashi

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lopes, R.H., Azevedo, B.R.B., Arvellos, A.N., Abreu-Reis, P., Oliveira, A.F. (2020). Diagnosis of Colorectal Liver Metastases. In: Correia, M., Choti, M., Rocha, F., Wakabayashi, G. (eds) Colorectal Cancer Liver Metastases. Springer, Cham. https://doi.org/10.1007/978-3-030-25486-5_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-25486-5_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-25485-8

  • Online ISBN: 978-3-030-25486-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation